Potassium chloride

Identification

Name
Potassium chloride
Accession Number
DB00761
Description

A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives.

Type
Small Molecule
Groups
Approved, Withdrawn
Structure
Thumb
Weight
Average: 74.551
Monoisotopic: 73.932559568
Chemical Formula
ClK
Synonyms
  • Chlorid draselny
  • Chloride of potash
  • Kaliumchlorid
  • KCl
  • Monopotassium chloride
  • Muriate of potash
  • Sylvite
External IDs
  • B1653
  • E 508
  • E-508
  • INS NO.508
  • INS-508
  • NSC-77368

Pharmacology

Indication

For use as an electrolyte replenisher and in the treatment of hypokalemia.

Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

The potassium ion is in the principle intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle, and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops as a consequence of therapy with diuretics, primarily or secondary hyperaldosteronism, diabetic ketoacidosis, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Depletion can develop rapidly with severe diarrhea, especially if associated with vomiting. Potassium depletion due to these causes is usually accompanied by concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may produce weakness, fatigue, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and, in advanced cases, flaccid paralysis and/or impaired ability to concentrate urine. If potassium depletion associated with metabolic alkalosis cannot be managed by correcting the fundamental cause of the deficiency, e.g., where the patient requires long-term diuretic therapy, supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels. In rare circumstances (e.g., patients with renal tubular acidosis) potassium depletion may be associated with metabolic acidosis and hyperchloremia. In such patients, potassium replacement should be accomplished with potassium salts other than the chloride, such as potassium bicarbonate, potassium citrate, potassium acetate, or potassium gluconate.

Mechanism of action

Supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels.

TargetActionsOrganism
USolute carrier family 12 member 2Not AvailableHumans
USolute carrier family 12 member 1
binder
Humans
USolute carrier family 12 member 5Not AvailableHumans
USolute carrier family 12 member 6Not AvailableHumans
USolute carrier family 12 member 7Not AvailableHumans
USolute carrier family 12 member 4Not AvailableHumans
Absorption

Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Potassium is a normal dietary constituent and, under steady-state conditions, the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake.

Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired, of if potassium is administered too rapidly intravenously, potentially fatal hyperkalemia can result. It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5-8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-wave, depression of S-T segment, and prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9-12 mEq/L).

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirPotassium chloride may decrease the excretion rate of Abacavir which could result in a higher serum level.
AcarboseAcarbose may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
AcebutololPotassium chloride may increase the hyperkalemic activities of Acebutolol.
AceclofenacAceclofenac may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Potassium chloride which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
AclidiniumThe risk or severity of gastrointestinal ulceration can be increased when Aclidinium is combined with Potassium chloride.
AcrivastinePotassium chloride may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Take with a full glass of water.
  • Take with food. This reduces gastrointestinal irritation.

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Active Moieties
NameKindUNIICASInChI Key
Potassium cationionic295O53K15224203-36-9NPYPAHLBTDXSSS-UHFFFAOYSA-N
Chloride ionionicQ32ZN4869816887-00-6VEXZGXHMUGYJMC-UHFFFAOYSA-M
Product Images
International/Other Brands
Kaon Cl / Kaon-CL 10 / Micro-K / Sando-K / Slow-K
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Chlorure de potassium ProampInjection, solution, concentrate0.15 g/1mLIntravenousLaboratoire Aguettant2018-07-31Not applicableUS flag
EpiklorPowder, for solution1.5 g/1.77gOralEpic Pharma, LLC2010-02-012013-10-01US flag
Epiklor/25Powder, for solution1.875 g/2.21gOralEpic Pharma, LLC2010-02-012013-09-01US flag
HUMCO Potassium Chloride 10 PercentLiquid100 mg/1mLOralHumco Holding Group. Inc.1979-01-012015-12-31US flag
K + 45LiquidHemodialysisBaxter Laboratories1990-12-31Not applicableCanada flag
K C1-rougierLiquidOralRougier Pharma Division Of Ratiopharm Inc1967-12-311999-09-27Canada flag
K Lor Granules 20meqPowder, for solutionOralAbbott1979-12-312008-06-06Canada flag
K-durTablet, extended release1500 mg/1OralMerck Sharp & Dohme Limited1986-06-132008-10-31US flag
K-durTablet, extended release1.5 gOralMerck Ltd.1989-12-312014-12-04Canada flag
K-durTablet, extended release750 mg/1OralMerck Sharp & Dohme Limited1986-06-132008-10-31US flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Klor Con MTablet, extended release1500 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1998-11-20Not applicableUS flag00245 0058 01 nlmimage10 bb345de2
Klor Con MTablet, extended release750 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1998-11-20Not applicableUS flag
Klor-ConTablet, extended release1500 mg/1OralApace Packaging2000-08-092014-09-30US flag
Klor-conPowder, for solution1.5 g/1OralUpsher-Smith Laboratories, LLC2017-10-23Not applicableUS flag
Klor-Con MTablet, extended release1500 mg/1OralMed Health Pharma LLC2011-05-102012-06-10US flag
Klor-Con MTablet, extended release1500 mg/1OralPhysicians Total Care, Inc.2005-08-152011-06-30US flag
Klor-con MTablet, extended release750 mg/1OralCardinal Health2014-09-012021-05-31US flag
Klor-con MTablet, extended release1125 mg/1OralUpsher-Smith Laboratories, LLC2011-01-18Not applicableUS flag
Klor-con MTablet, extended release750 mg/1OralSandoz Inc.2011-01-182021-10-31US flag
Klor-con MTablet, extended release750 mg/1OralREMEDYREPACK INC.2019-02-222020-06-01US flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Hi Potency Potassium ChlorideTablet, extended releaseOralSwiss Herbal Remedies Ltd.1997-02-242001-08-02Canada flag
Kaochlor-20SolutionOralPfizer Canada Ulc1995-12-312006-08-02Canada flag
Micro-K-10 Extencaps Src 750mgCapsule, extended releaseOralWyeth Ayerst Canada Inc.1994-12-312003-07-28Canada flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
(20 Mmol/l) Potassium Chloride In 3.3% Dextrose and 0.3% Sodium Chloride Injection USPPotassium chloride (150 mg) + Dextrose, unspecified form (3.3 g) + Sodium chloride (300 mg)SolutionIntravenousBaxter Laboratories1978-12-31Not applicableCanada flag
(20 Mmol/l) Potassium Chloride In 5% Dextrose and 0.9% Sodium Chloride Injection USPPotassium chloride (150 mg) + Dextrose, unspecified form (5 g) + Sodium chloride (900 mg)SolutionIntravenousBaxter Laboratories1990-12-31Not applicableCanada flag
(20 Mmol/l) Potassium Chloride In 5% Dextrose Injection USPPotassium chloride (150 mg) + Dextrose, unspecified form (5 g)SolutionIntravenousBaxter Laboratories1989-12-31Not applicableCanada flag
(20mmol/l) Potassium Chloride In 0.9% Sodium Chloride Injection USPPotassium chloride (150 mg) + Sodium chloride (900 mg)SolutionIntravenousBaxter Laboratories1989-12-31Not applicableCanada flag
(20mmol/l) Potassium Chloride In 5% Dextrose and 0.2% Sodium Chloride Injection USPPotassium chloride (150 mg) + Dextrose, unspecified form (5 g) + Sodium chloride (200 mg)SolutionIntravenousBaxter Laboratories1989-12-312016-07-15Canada flag
(20mmol/l) Potassium Chloride In 5% Dextrose and 0.45% Sodium Chloride Injection USPPotassium chloride (150 mg) + Dextrose, unspecified form (5 g) + Sodium chloride (450 mg)SolutionIntravenousBaxter Laboratories1989-12-31Not applicableCanada flag
(40 Mmol/l) Potassium Chloride In 0.9% Sodium Chloride Injection USPPotassium chloride (300 mg) + Sodium chloride (900 mg)LiquidIntravenousBaxter Laboratories1989-12-31Not applicableCanada flag
(40 Mmol/l) Potassium Chloride In 5% Dextrose Injection USPPotassium chloride (300 mg) + Dextrose, unspecified form (5 g)SolutionIntravenousBaxter Laboratories1989-12-31Not applicableCanada flag
(40 Mmols/l) Potassium Chloride In Lactated Ringer's Injection USPPotassium chloride (328 mg) + Calcium chloride (20 mg) + Sodium lactate (310 mg) + Sodium chloride (600 mg)SolutionIntravenousBaxter Laboratories2002-12-112016-07-15Canada flag
(40mmol/l) Potassium Chloride In 3.3% Dextrose and 0.3% Sodium Chloride Injection USPPotassium chloride (300 mg) + Dextrose, unspecified form (3.3 g) + Sodium chloride (300 mg)SolutionIntravenousBaxter Laboratories1978-12-31Not applicableCanada flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Chlorure de potassium ProampPotassium chloride (0.15 g/1mL)Injection, solution, concentrateIntravenousLaboratoire Aguettant2018-07-31Not applicableUS flag
Cytosol Ophthalmics - Balanced Salt SolutionPotassium chloride (75 mg/1mL) + Calcium chloride dihydrate (48 mg/1mL) + Magnesium chloride hexahydrate (30 mg/1mL) + Sodium acetate trihydrate (3.90 mg/1mL) + Sodium chloride (6.40 mg/1mL) + Sodium citrate dihydrate (1.70 mg/1mL)SolutionIrrigationBiomet Biologics2010-01-012010-09-04US flag
Effervescent Potassium ChloridePotassium chloride (1.25 g/1) + L-Lysine hydrochloride (1.5 g/1) + Potassium bicarbonate (0.7 g/1)Tablet, effervescentOralQualitest2006-01-062021-07-31US flag
EpiklorPotassium chloride (1.5 g/1.77g)Powder, for solutionOralEpic Pharma, LLC2010-02-012013-10-01US flag
Epiklor/25Potassium chloride (1.875 g/2.21g)Powder, for solutionOralEpic Pharma, LLC2010-02-012013-09-01US flag
Glysol-500Potassium chloride (0.03 g/100mL) + Glycerin (57.10 g/100mL) + Sodium lactate (1.60 g/100mL)SolutionExtracorporealBiomet Biologics2010-01-012010-09-06US flag
HUMCO Potassium Chloride 10 PercentPotassium chloride (100 mg/1mL)LiquidOralHumco Holding Group. Inc.1979-01-012015-12-31US flag
HydroGold 9Potassium chloride (0.01 mg/100mg) + Acetyl hexapeptide-3 (0.01 mg/100mg) + Adenosine (0.04 mg/100mg) + Allantoin (0.2 mg/100mg) + Sodium benzoate (0.5 mg/100mg) + Butylene glycol (2 mg/100mg) + Castor oil (0.4 mg/100mg) + Dimethicone (0.01 mg/100mg) + Glycerin (20 mg/100mg) + Gold (0.0001 mg/100mg) + Nicotinamide (2 mg/100mg) + Phenoxyethanol (0.5 mg/100mg) + Titanium dioxide (0.43 mg/100mg) + Xanthan gum (0.5 mg/100mg)PatchTopicalBhmbg Global Branding Inc.2018-03-092019-12-31US flag
K-SolPotassium chloride (20 meq/15mL)LiquidOralLaser Pharmaceuticals Llc2015-01-222015-12-31US flag
K-SolPotassium chloride (40 meq/15mL)LiquidOralLaser Pharmaceuticals Llc2015-01-222015-12-31US flag

Categories

ATC Codes
A12BA51 — Potassium chloride, combinationsB05XA01 — Potassium chlorideA12BA01 — Potassium chloride
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as alkali metal chlorides. These are inorganic compounds in which the largest halogen atom is Chlorine, and the heaviest metal atom is an alkali metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkali metal salts
Sub Class
Alkali metal chlorides
Direct Parent
Alkali metal chlorides
Alternative Parents
Inorganic chloride salts
Substituents
Alkali metal chloride / Inorganic chloride salt / Inorganic salt
Molecular Framework
Not Available
External Descriptors
potassium salt, inorganic chloride (CHEBI:32588)

Chemical Identifiers

UNII
660YQ98I10
CAS number
7447-40-7
InChI Key
WCUXLLCKKVVCTQ-UHFFFAOYSA-M
InChI
InChI=1S/ClH.K/h1H;/q;+1/p-1
IUPAC Name
potassium chloride
SMILES
[Cl-].[K+]

References

Synthesis Reference

Fritz Hagedorn, Gerd Peuschel, Arno Singewald, "Method for the production of potassium chloride with K.sub.2 O content of more than 55 weight percent." U.S. Patent US5057208, issued July, 1955.

US5057208
General References
Not Available
KEGG Drug
D02060
PubChem Compound
4873
PubChem Substance
46506038
ChemSpider
4707
RxNav
8591
ChEBI
32588
ChEMBL
CHEMBL1200731
Therapeutic Targets Database
DAP000828
PharmGKB
PA451055
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Potassium_chloride
AHFS Codes
  • 40:34.00* — Hemodialysis Solution
  • 88:29.00* — Minerals
  • 40:12.00 — Replacement Preparations
FDA label
Download (632 KB)
MSDS
Download (72.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedNot AvailableColonoscopy1
4CompletedBasic ScienceBlood Pressures / High Blood Pressure (Hypertension)1
4CompletedBasic ScienceFunctional Constipation / Irritable Bowel Syndrome Characterized by Constipation1
4CompletedDiagnosticColon Adenomas / Colon Lesion / Colon Polyps1
4CompletedScreeningColorectal Cancers1
4CompletedTreatmentArthroplasty, Knee Replacement1
4CompletedTreatmentAtrial Fibrillation (AF) / Flutter, Atrial1
4CompletedTreatmentBowel Preparation for Colonoscopy1
4CompletedTreatmentCesarean Section / Hypotension / Pregnancy / Spinal Anaesthesia1
4CompletedTreatmentColon Cleansing1

Pharmacoeconomics

Manufacturers
  • Novo nordisk inc
  • Savage laboratories inc div altana inc
  • Kv pharmaceutical co
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc florida
  • Abraxis pharmaceutical products
  • Akorn inc
  • App pharmaceuticals llc
  • B braun medical inc
  • Baxter healthcare corp anesthesia and critical care
  • Baxter healthcare corp
  • Gd searle llc
  • Hospira inc
  • International medication system
  • Eli lilly and co
  • Luitpold pharmaceuticals inc
  • Miles laboratories inc
  • Pharma serve inc sub torigian laboratories
  • Watson laboratories inc
  • Future pak ltd
  • Upsher smith laboratories inc
  • Apothecon inc div bristol myers squibb
  • Abbott laboratories pharmaceutical products div
  • Copley pharmaceutical inc
  • Eurand america inc
  • Schering corp
  • Novartis pharmaceuticals corp
  • Upsher-Smith Laboratories Inc.
Packagers
  • Abbott Laboratories Ltd.
  • Actavis Group
  • Advanced Pharmaceutical Services Inc.
  • Alaven Pharmaceutical
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apace Packaging
  • Apothecon
  • APP Pharmaceuticals
  • A-S Medication Solutions LLC
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Bristol-Myers Squibb Co.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Caremark LLC
  • Century Pharmaceuticals Inc.
  • Chemrich Laboratories Inc.
  • Comprehensive Consultant Services Inc.
  • Corvit Pharmaceuticals
  • Coupler Enterprises Inc.
  • Dept Health Central Pharmacy
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Edwards Pharmaceuticals
  • Epic Pharma LLC
  • Ethex Corp.
  • Eurand Pharmaceuticals Inc.
  • Forest Pharmaceuticals
  • General Injectables and Vaccines Inc.
  • H and H Laboratories
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Hospira Inc.
  • Humco
  • John Ross Chemical Ltd.
  • Kaiser Foundation Hospital
  • KV Pharmaceutical Co.
  • Laboratoires Upsa
  • Lake Erie Medical and Surgical Supply
  • Legacy Pharmaceuticals Packaging LLC
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Mallinckrodt Inc.
  • Mckesson Corp.
  • Mead Johnson and Co.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Neighborcare Repackaging Inc.
  • Neuman Distributors Inc.
  • Novartis AG
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Association
  • Pharmaceutical Packaging Center
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmacia Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Qualitest
  • Rebel Distributors Corp.
  • Remedy Repack
  • Sandhills Packaging Inc.
  • Sandoz
  • Savage Labs
  • Schering Corp.
  • Schering-Plough Inc.
  • Southwood Pharmaceuticals
  • Summit Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Ther-Rx Corp.
  • Tower Laboratories Ltd.
  • Tya Pharmaceuticals
  • United Research Laboratories Inc.
  • Upsher Smith Laboratories
  • Va Cmop Dallas
  • Vangard Labs Inc.
  • Vintage Pharmaceuticals Inc.
  • Warrick Pharmaceuticals Corp.
  • Watson Pharmaceuticals
  • Wockhardt Ltd.
Dosage Forms
FormRouteStrength
SolutionIntravenous5 %
Injection, solutionIntravenous150 mg/100mL
Injection, solutionIntravenous5 g/100mL
LiquidIntravenous
Injection, solutionIntravenous300 mg/100mL
SolutionHemodialysis0.257 g/1000ml
SolutionHemodialysis2.94 g/1000ml
SolutionExtracorporeal7.52 g/L
SolutionHemodialysis
LiquidHemodialysis
Granule, for solutionOral370 mg
Tablet, extended releaseOral750 mg
SolutionIntravenous0.25 g/mL
Injection, solutionIntravenous2.5 g/500mL
SolutionIntravenous1.79 g/L
Powder, for solutionIntraocular
SolutionIntraocular
SolutionOral289.2 mg
SolutionOral5 mg/1mL
Injection, solutionIntravenous6 g/L
SolutionIntravenous0.4 g/1000ml
InjectionIntravenous0.03 g/100ml
SolutionParenteral100 mg/ml
InjectionIntravenous14.9 %
InjectionIntravenous7.45 %
Powder, for solutionOral5.97 g/7.288g
Powder, for solutionOral2.99 g/3.645g
SolutionOphthalmic
SolutionIntraocular; Irrigation1950 mg
Kit; powder, for solution; tablet, delayed releaseOral
SolutionIntravenous0.64 g/100ml
SolutionIntravenous5 g/100ml
SolutionIntravenous0.03 g/100ml
SolutionIntravenous0.86 g/100ml
SolutionIntravenous50 g/L
SolutionIntravenous3.1 g/L
Injection, solutionIntravenous3.1 g/L
SolutionHemodialysis; Intravenous3.05 g/L
SolutionIntravenous3.05 g/L
SolutionIrrigation48 mg/100mL
Kit; solutionIntraocular
SolutionIrrigation0.433 mg/1mL
Injection, solutionIntracardiac2.5 mmol/50mL
SolutionIntra-arterial
Solution6340 mg/L
Injection, solution, concentrateIntravenous0.15 g/1mL
SolutionIntravenous1.491 g
SolutionIntravenous20 mEq/mL
Solution970 mg/100mL
Powder, for solutionNasogastric
Powder, for solutionOral45 g/750mL
SolutionIntravenous0.27 g/L
SolutionExtracorporeal0.0022 g/L
SolutionIrrigation
Injection, solutionIntracardiac3.25 g/1mL
SolutionIntravenous6.4 g/L
InjectionIntravenous
Powder, for solutionOral3.375 g/5.5g
SolutionIntravenous4.21 g/1000ml
SolutionHemodialysis1.98 g/1000ml
SolutionHemodialysis0.91 g/1000ml
Injection, solutionIntravenous10.39 g/L
Tablet, effervescentOral
Granule, for solutionOral1.5 g
SolutionOral12.27 g/100mL
PowderOral
SolutionIntrathecal
InjectionIntrathecal
SolutionParenteral1.864 g
SolutionParenteral6.124 g
SolutionParenteral0.61 g
SolutionIntravenous0.298 mg/ml
SolutionParenteral0.186 g
SolutionIntravenous; Subcutaneous0.3 g/1000ml
SolutionIntravenous1.193 g/250ml
Powder, for solutionOral52500 g
PowderOral52.5 g
Granule, for solutionOral650 mg
Powder, for solutionOral2.9 g
Tablet, delayed releaseOral500 mg
SolutionOral0.294 g
Powder, for solutionOral1.5 g/1.77g
Powder, for solutionOral1.875 g/2.21g
EmulsionParenteral3.99 g/1085ml
EmulsionParenteral2.05 g/1085ml
Powder, for solutionOral0.75 g/73.69g
SolutionIntravenous0.15 g/L
SolutionParenteral0.2 g
SolutionIntravenous1.63 g
SolutionParenteral0.336 g
PowderOral13.5 g
SprayOral7.3 mg/50mL
Aerosol, sprayOral0.0026 g/50ml
SolutionUnknown
SolutionExtracorporeal
Powder, for solutionNasogastric; Oral
Powder, for solutionOral1.916 g/3.3g
SolutionHemodialysis2.4 g/1000ml
LiquidHemodialysis9.74 g/L
Solution, concentrate9 g/1L
Solution, concentrate6.43 g/1L
SolutionOral30 mg
SolutionOral0.29 g
SolutionOral0.275 g
SolutionOral275 mg
LiquidOral100 mg/1mL
PatchTopical
SolutionIntravenous3 g
SolutionIntravenous0.31 %
Injection, solutionIntravenous29.4 mg/100mL
Solution, concentrateIntravenous100 mmol/L
Solution, concentrateIntravenous200 mmol/L
Solution, concentrateIntravenous400 mmol/L
Injection, solutionIntravenous0.15 %w/v
Injection, solutionIntravenous0.9 %
SolutionIntravenous0.02 g
LiquidIntraocular
Solution0.64 g/100ml
SolutionIntravenous0.64 %
SolutionIntravenous0.03 %
SolutionIntravenous0.37 %
SolutionIntravenous
LiquidHemodialysis
Tablet, extended releaseOral1.5 g
Powder, for solutionOral
TabletOral
LiquidOral20 meq/15mL
LiquidOral40 meq/15mL
Tablet, film coated, extended releaseOral1500 mg/1
Tablet, film coated, extended releaseOral750 mg/1
Injection, solution, concentrateIntravenous1.5 g/10mL
Injection, solution, concentrateIntravenous150 mg/1mL
SolutionIntravenous0.07 g
Injection, emulsionIntravenous
Injection, emulsionIntravenous467 mg/100mL
InjectionIntravenous110 g
InjectionIntravenous165 g
InjectionIntravenous220 g
InjectionIntravenous275 g
InjectionIntravenous107 g
InjectionIntravenous143 g
InjectionIntravenous178 g
Capsule, extended releaseOral600 mg
Tablet, extended releaseOral
SolutionIntravenous1.491 g/20ml
Injection, solution, concentrateIntravenous74.5 mg/ml
Injection, solution, concentrateIntravenous15 %
SolutionIntravenous8.6 %
SolutionOral
CapsuleOral840 mg
Injection, solution, concentrateIntravenous200 meq/100mL
SolutionOral1 meq/1mL
Syrup10 g/100mL
SolutionOral5 mg/100mL
SolutionOral60 mg/5mL
Tablet, extended releaseOral600 MG
Tablet, sugar coatedOral600 mg
Powder, for solutionOral1.685 g
Powder, for solutionOral1.875 g/1
Powder, for solutionOral20 meq/1
Tablet, extended releaseOral750 mg/1
Tablet, extended releaseOral10 meq/1
Tablet, extended releaseOral1125 mg/1
Tablet, extended releaseOral20 meq/1
SolutionIntravenous20.475 %
Tablet, film coated, extended releaseOral
SolutionIntravenous20 mg/100ml
Injection, solutionIntravenous30 mg/100mL
Solution, for slushIrrigation
SolutionIntravenous20 mg
SolutionIntravenous; Irrigation0.2 mg
Injection, solutionIntravenous50 mg/mL
Injection, solutionIntravenous3 g/L
Injection, solutionIntravenous3.14 g/L
SolutionIntravenous7.5 %
Powder, for solutionOral0.05 g
Powder, for solutionOral0.3507 g
PowderOral3.5 g
SolutionOral20 meq/30mL
PowderOral5 g/100mL
Powder, for solutionOral13.125 G
EmulsionTopical
Capsule, delayed releaseOral600 mg
Capsule, extended releaseOral
Capsule, extended releaseOral750 mg/1
Capsule, extended releaseOral600 mg/1
LiquidBuccal
SprayBuccal
SolutionOral13.125 g
Powder, for solutionOral350.7 mg
Powder, for solutionOral6.563 G
Powder, for solutionOral0.1785 g
Powder, for solutionOral0.0251 g
Injection, solution, concentrateOral0.3507 g
KitOral
SolutionOral100 g
Powder, for solutionOral4.7 g
Powder, for solutionOral7.5 g
SolutionHemodialysis0.2205 g/1000ml
Injection, solutionHemodialysis; Intravenous6.136 g/1000ml
SolutionHemodialysis0.2205 g/L
SolutionIntravenous0.368 g
Powder, for solutionOral658 mg
Kit; solutionIntraocular; Irrigation
Granule, effervescentOral
SolutionIntravenous55 g/L
SolutionIntravenous5.5 g/100ml
SolutionIntravenous0.53 g/100ml
SolutionIntravenous0.86 %
SolutionIntravenous16 g/L
Powder, for solutionOral118 g
Powder, for solutionOral0.875 g
Powder, for solutionOral0.3 g
Injection, emulsionIntravenous1.6 g/100mL
Injection, emulsion; injection, solutionIntravenous3.2 g/100mL
Injection, solution, concentrateIntravenous
SolutionOral13.5 g/1L
SolutionOral
Injection, emulsionIntravenous12 g/1500ml
Injection, emulsionIntravenous32 g/1000ml
Injection, emulsionIntravenous0.52 g/1000ml
Injection, emulsionIntravenous0.42 g/1000ml
Injection, emulsionIntravenous1.6 g
InjectionIntravenous2.27 g/l
InjectionIntravenous4.12 g/l
SolutionIntravenous7.14 g
SolutionIntravenous9.52 g
SolutionIntravenous11.9 g
EmulsionIntravenous6.41 g
EmulsionIntravenous9.61 g
EmulsionIntravenous12.82 g
Injection, emulsionIntravenous6.41 g/1000ml
EmulsionIntravenous4 g
Injection, emulsionIntravenous8.24 g/1000ml
Solution, concentrateOral1.9 mg
Powder, for solutionOral3 g/4.5g
Powder, for solutionOral15 g/22.5g
SolutionIntraocular; Ophthalmic7.8 mg
Powder, for solutionOral13 g/15g
Powder, for solutionOral5 g/6.975g
Powder, for solutionOral3.24 g
Powder, for solutionOral10.125 g/16.5g
Powder, for solutionOral2.025 g/3.3g
SolutionExtracorporeal; Intrabiliary; Intracardiac0.671 g/L
Injection, solutionIntraperitoneal3 g/5g
Powder, for solutionOral3.375 g
Granule, for solutionOral3 g
Powder, for solutionOral5 g/7.5g
InjectionIntravenous7.46 %
Powder, for solutionOral59 g
Syrup0.447 meq/1mL
SolutionOral294 mg
SolutionOral29.4 mg
Powder, for solutionOral568 mg
Powder, for solutionOral120 g/129.2g
Powder, for solutionOral46.6 mg
LiquidOral
Injection, solutionIntravenous3 g/100ml
EmulsionParenteral1.26 g
EmulsionIntravenous
EmulsionIntravenous3 g
Injection, emulsionIntravenous3.66 g
Injection, emulsionIntravenous5.5 g
Injection, emulsionIntravenous7.33 g
Injection, emulsionIntravenous9.16 g
Injection, emulsionIntravenous3.66 g/1000ml
Injection, solutionIntravenous5 %
InjectionIntravenous10 % w/v
SolutionHemodialysis0.225 g/1000ml
SolutionHemodialysis3.68 g/L
IrrigantIrrigation
SolutionIntravenous368 mg
Injection, solutionIntravenous
SolutionParenteral3.68 g/l
Injection, solutionIntra-arterial
Solution
Powder, for solutionOral100 g
SolutionIntravenous0.035 %
Injection, solutionIntravenous0.03 %
SolutionIntravenous3.2 g/100mL
SolutionIntravenous1.6 g/100mL
Powder, for solutionOral
SolutionOral500 mg/5mL
Injection, solutionIntravenous22.5 %
Injection, solutionIntravenous7.5 %
Syrup500 mg/5mL
CapsuleOral750 mg/1
Capsule, coated, extended releaseOral10 meq/1
Capsule, coated, extended releaseOral8 meq/1
Capsule, extended releaseOral10 meq/1
Capsule, extended releaseOral8 meq/1
For solutionOral1.5 g/1.58g
For solutionOral1.5 g/1.54g
InjectionIntravenous150 g/1000mL
Injection, solutionIntravenous1.5 g/10mL
Injection, solutionIntravenous10 meq/100mL
Injection, solutionIntravenous14.9 g/1000mL
Injection, solutionIntravenous15 g/100mL
Injection, solutionIntravenous200 meq/1000mL
Injection, solutionIntravenous22.4 g/1000mL
Injection, solutionIntravenous29.8 g/1000mL
Injection, solutionIntravenous30 meq/100mL
Injection, solutionIntravenous40 meq/20mL
Injection, solutionIntravenous400 meq/1000mL
Injection, solutionIntravenous7.46 g/1000mL
Injection, solution, concentrateIntravenous149 mg/1mL
Injection, solution, concentrateIntravenous2 meq/1mL
Injection, solution, concentrateParenteral14.9 g/100mL
LiquidOral40 meq/30mL
PowderOral20 meq/1.5g
Powder, for solutionOral1.5 g/1.74g
Powder, for solutionOral1.5 g/1
Powder, for solutionOral25 meq/1
SolutionOral1.3 meq/1mL
SolutionOral1.5 g/15mL
SolutionOral10 g/100mL
SolutionOral2.6 meq/1mL
SolutionOral20 meq/15mL
SolutionOral3 g/15mL
SolutionOral40 meq/15mL
Syrup1 meq/1mL
TabletOral10 meq/1
TabletOral1125 mg/1
TabletOral1500 mg/1
TabletOral500 mg
TabletOral750 mg/1
Tablet, extended releaseOral1500 mg/1
Tablet, extended releaseOral8 meq/1
Tablet, film coated, extended releaseOral10 meq/1
Tablet, film coated, extended releaseOral600 mg/1
Tablet, film coated, extended releaseOral8 meq/1
SolutionOral10 mg/100mL
SolutionOral3 mg/100mL
SolutionOral375 mg/5mL
SolutionOral7.5 g/100mL
SolutionOral13 meq/15mL
TabletOral20 meq/1
CapsuleOral600 mg/1
Powder, for solutionOral1.5 g/1.58g
SolutionIntravenous
LiquidIntravenous
Injection, solution, concentrateIntravenous10 % W/V
InjectionIntravenous15 %
SolutionOral6.67 g/100mL
PowderHemodialysis
Injection, solution, concentrateIntravenous20 meq/10mL
Injection, solution, concentrateIntravenous40 meq/20mL
InjectionIntravenous225 mg/1ml
InjectionIntravenous75 mg/1ml
SolutionOral40 meq/30mL
TabletOral600 MG
KitHemodialysis
SolutionHemodialysis; Intravenous
SolutionIntravenous2.033 g/L
SolutionHemodialysis0.257 g/L
Injection, solutionIntravenous0.86 g/100mL
SolutionParenteral3 g/100ml
DoucheVaginal
Powder, for solutionOral3 g/4.2g
Powder, for solutionOral520 mg
SolutionParenteral6 g/l
SolutionParenteral8.6 g/l
SolutionIntravenous0.6 g/100ml
SolutionIntravenous0.31 g/100ml
SolutionIrrigation; Topical20 mg
SolutionParenteral0.4 g/l
Injection, solutionIntravenous0.27 g/l
SolutionParenteral9 g/l
Injection, solutionIntravenous0.3 g/l
Injection, solutionIntravenous20 mg/100mL
SolutionParenteral0.33 g/l
LiquidOral
SolutionBuccal; Oral; Topical16.2 mg
AerosolOral
Powder, for solutionOral15 g/21.75g
Powder, for solutionOral3.242 g/5.09g
Powder, for solutionOral1.621 g/2.54g
Powder, for solutionOral10.13 g/15.9g
Powder, for solutionOral4.8 g/6.99g
Granule700 mg
Granule50 gr
SprayOral5 mg
Tablet, extended releaseOral600 mg/1
EmulsionParenteral1.6 g/l
EmulsionParenteral0.61 g/l
EmulsionParenteral440 mg
Injection, emulsionIntravenous4.4 g/1000ml
EmulsionParenteral3.1 g
Injection, emulsionIntravenous7.1 g/1000ml
EmulsionParenteral50 g
SolutionIntravenous0.2 mg
SolutionIntravenous6 mg
SolutionIntravenous33 mg
SolutionConjunctival; Ophthalmic12.5 mg
SolutionIntraocular; Irrigation0.39 g
Powder, for solutionOral1.8 g/2.519g
Injection, solutionIntracardiac13.54 mg/20mL
ConcentrateIntravenous drip14 mg/ml
SolutionParenteral0.51 g
SolutionParenteral50 g
SolutionParenteral5.552 g
SolutionIntravenous0.3 g
SolutionParenteral0.67 g
SolutionIntravenous0.37 g/L
EmulsionParenteral0.28 g
EmulsionParenteral0.18 g
SolutionIntravenous0.6 g/L
TabletOral
LiquidIrrigation
Powder, for solutionOral1.43 g
Injection, solution3.6 mg/100mL
SolutionIntravenous; Irrigation0.62 g/100ml
SolutionIntravenous10 mg/2ml
Granule, for solutionOral6.25 mg
Powder, for solutionOral375 mg
SolutionIntravenous6 g/100mL
Injection, solutionIntravenous30 g/500mL
EmulsionParenteral2.24 g
EmulsionParenteral4.34 g
EmulsionParenteral3.95 g
EmulsionParenteral28 g/1000ml
Prices
Unit descriptionCostUnit
Klor-Con 100 20meq Packets Box106.77USD box
Kay Ciel 30 20meq Packets Box58.99USD box
Rum-K-SF 15% Liquid 473ml Bottle45.98USD bottle
Klor-Con 30 25meq Packets Box36.99USD box
Colyte 240 gm Solution26.0USD bottle
Colyte-Flavored 240 gm Solution18.17USD bottle
K-Lor 20meq Packets1.92USD packet
K-lyte tablet eff1.43USD tablet
K-lyte-cl 25 meq tablet eff1.43USD tablet
Micro-K 10meq capsule1.41USD capsule
Micro-K 8meq capsule1.21USD capsule
Potassium cl 25 meq tablet eff0.94USD tablet
Micro-k 10 meq extencaps0.91USD each
Potassium Chloride CR 10meq capsule0.9USD capsule
Potassium Chloride CR 8meq capsule0.87USD capsule
K-Tabs 10meq Controlled Release Tabs0.68USD tab
K-tab er 10 meq tablet0.66USD tablet
Kaochlor-eff 20 meq tablet0.59USD tablet
K-tab 10 meq tablet sa0.58USD tablet
K-Lyte 25 meq Effervescent Tablet0.58USD tablet
Klor-con m20 tablet0.57USD tablet
Klor-Con/EF 25meq Effervescent Tabs0.57USD tab
Klor-Con 8meq Controlled Release Tabs0.56USD tab
Klor-Con M20 20meq Controlled Release Tabs0.55USD tab
Potassium Chloride Crys CR 20meq Controlled Release Tabs0.53USD tab
Potassium cl 20 meq tablet er0.52USD tablet
Potassium cl 20 meq tablet sa0.52USD tablet
Klor-con 10 meq tablet0.5USD tablet
Klor-con m15 tablet0.5USD tablet
Klotrix 10meq Controlled Release Tabs0.5USD tab
Potassium cl er 20 meq tablet0.49USD tablet
Klor-con-ef 25 meq tablet eff0.4USD tablet
Micro-k 8 meq extencaps0.34USD each
Kaon-Cl-10 10meq Controlled Release Tabs0.3USD tab
Klor-con m10 tablet0.3USD tablet
Potassium cl er 10 meq tablet0.3USD tablet
Potassium cl 10 meq tablet sa0.29USD tablet
Potassium Chloride Crys CR 10meq Controlled Release Tabs0.28USD tab
Potassium Chloride CR 10meq Controlled Release Tabs0.27USD tab
Potassium cl er 8 meq tablet0.26USD tablet
Kaon-cl 10 meq tablet sa0.23USD tablet
Potassium cl 2 meq/ml vial0.23USD ml
K-Dur 20 meq Sustained-Release Tablet0.21USD tablet
Potassium Chloride CR 8meq Controlled Release Tabs0.18USD tab
Klor-con 8 meq tablet0.16USD tablet
Slow K 8 meq Sustained-Release Tablet0.16USD tablet
Micro-K Extencaps 8 meq Sustained-Release Capsule0.1USD capsule
Apo-K 8 meq Sustained-Release Tablet0.09USD tablet
Potassium Chloride 40 Meq/15ml(20%) Liquid0.06USD ml
Potassium Chloride 20 Meq/15ml(10%) Liquid0.03USD ml
Potassium chloride crystals0.02USD g
K-10 Oral Liquid 1.33 meq/ml Liquid0.02USD ml
Colyte with flavor packets0.01USD ml
Pms - Potassium Chloride 1.33 meq/ml Liquid0.01USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US7291324No2007-11-062022-10-22US flag
US7169381No2007-01-302024-09-01US flag
US7658914No2010-02-092024-09-01US flag
US7084130No2006-08-012021-11-29US flag
US9326969No2016-05-032033-09-10US flag
US9592252No2017-03-142032-08-11US flag
US9707297No2017-07-182033-09-10US flag
US8999313No2015-04-072033-09-10US flag
US10016504No2018-07-102033-09-10US flag
US10646512No2012-03-252032-03-25US flag
US10792306No2012-03-092032-03-09US flag
US10780112No2012-03-092032-03-09US flag
Additional Data Available
  • Filed On
    Filed On
    Available for Purchase

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)770 °CNot Available
water solubilityFreely solubleNot Available
Predicted Properties
PropertyValueSource
logP0.2ChemAxon
pKa (Strongest Acidic)-7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9445
Blood Brain Barrier+0.975
Caco-2 permeable+0.6764
P-glycoprotein substrateNon-substrate0.9039
P-glycoprotein inhibitor INon-inhibitor0.9891
P-glycoprotein inhibitor IINon-inhibitor0.9866
Renal organic cation transporterNon-inhibitor0.9219
CYP450 2C9 substrateNon-substrate0.8116
CYP450 2D6 substrateNon-substrate0.717
CYP450 3A4 substrateNon-substrate0.7571
CYP450 1A2 substrateNon-inhibitor0.7551
CYP450 2C9 inhibitorNon-inhibitor0.8594
CYP450 2D6 inhibitorNon-inhibitor0.9314
CYP450 2C19 inhibitorNon-inhibitor0.8365
CYP450 3A4 inhibitorNon-inhibitor0.9576
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9002
Ames testNon AMES toxic0.6808
CarcinogenicityCarcinogens 0.7523
BiodegradationReady biodegradable0.6815
Rat acute toxicity1.9786 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9433
hERG inhibition (predictor II)Non-inhibitor0.9634
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A2
Uniprot ID
P55011
Uniprot Name
Solute carrier family 12 member 2
Molecular Weight
131445.825 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Hebert SC: Bartter syndrome. Curr Opin Nephrol Hypertens. 2003 Sep;12(5):527-32. [PubMed:12920401]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Binder
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A1
Uniprot ID
Q13621
Uniprot Name
Solute carrier family 12 member 1
Molecular Weight
121449.13 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Fujiwara TM, Bichet DG: Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol. 2005 Oct;16(10):2836-46. Epub 2005 Aug 10. [PubMed:16093448]
  4. Bichet DG: Hereditary polyuric disorders: new concepts and differential diagnosis. Semin Nephrol. 2006 May;26(3):224-33. [PubMed:16713495]
  5. Pressler CA, Heinzinger J, Jeck N, Waldegger P, Pechmann U, Reinalter S, Konrad M, Beetz R, Seyberth HW, Waldegger S: Late-onset manifestation of antenatal Bartter syndrome as a result of residual function of the mutated renal Na+-K+-2Cl- co-transporter. J Am Soc Nephrol. 2006 Aug;17(8):2136-42. Epub 2006 Jun 28. [PubMed:16807401]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport in mature neurons. Transport occurs under isotonic conditions, but is activated 20-fold by cell swelling. Important for Cl(-) homeostasis in n...
Gene Name
SLC12A5
Uniprot ID
Q9H2X9
Uniprot Name
Solute carrier family 12 member 5
Molecular Weight
126182.49 Da
References
  1. Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 (KCC2) in the Purkinje cells of embryonic mouse cerebellum. Neurosci Res. 2007 Feb;57(2):322-5. Epub 2006 Nov 28. [PubMed:17134779]
  2. Tornberg J, Segerstrale M, Kulesskaya N, Voikar V, Taira T, Airaksinen MS: KCC2-deficient mice show reduced sensitivity to diazepam, but normal alcohol-induced motor impairment, gaboxadol-induced sedation, and neurosteroid-induced hypnosis. Neuropsychopharmacology. 2007 Apr;32(4):911-8. Epub 2006 Aug 16. [PubMed:16936706]
  3. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
  4. Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 in granule cells of the early postnatal mouse cerebellum with special reference to the synapse formation. Neuroscience. 2006 Dec;143(3):757-67. Epub 2006 Sep 27. [PubMed:17008020]
  5. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Rubidium ion transmembrane transporter activity
Specific Function
Mediates electroneutral potassium-chloride cotransport. May be activated by cell swelling. May contribute to cell volume homeostasis in single cells.
Gene Name
SLC12A6
Uniprot ID
Q9UHW9
Uniprot Name
Solute carrier family 12 member 6
Molecular Weight
127615.745 Da
References
  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [PubMed:16943364]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May mediate K(+) uptake into Deiters' cells in the cochlea and contribute to K(+) recycling in the inner ear....
Gene Name
SLC12A7
Uniprot ID
Q9Y666
Uniprot Name
Solute carrier family 12 member 7
Molecular Weight
119104.84 Da
References
  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [PubMed:16943364]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May contribute to cell volume homeostasis in single cells. May be involved in the regulation of basolateral C...
Gene Name
SLC12A4
Uniprot ID
Q9UP95
Uniprot Name
Solute carrier family 12 member 4
Molecular Weight
120648.73 Da
References
  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [PubMed:16943364]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A2
Uniprot ID
P55011
Uniprot Name
Solute carrier family 12 member 2
Molecular Weight
131445.825 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Hebert SC: Bartter syndrome. Curr Opin Nephrol Hypertens. 2003 Sep;12(5):527-32. [PubMed:12920401]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A1
Uniprot ID
Q13621
Uniprot Name
Solute carrier family 12 member 1
Molecular Weight
121449.13 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Fujiwara TM, Bichet DG: Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol. 2005 Oct;16(10):2836-46. Epub 2005 Aug 10. [PubMed:16093448]
  4. Bichet DG: Hereditary polyuric disorders: new concepts and differential diagnosis. Semin Nephrol. 2006 May;26(3):224-33. [PubMed:16713495]
  5. Pressler CA, Heinzinger J, Jeck N, Waldegger P, Pechmann U, Reinalter S, Konrad M, Beetz R, Seyberth HW, Waldegger S: Late-onset manifestation of antenatal Bartter syndrome as a result of residual function of the mutated renal Na+-K+-2Cl- co-transporter. J Am Soc Nephrol. 2006 Aug;17(8):2136-42. Epub 2006 Jun 28. [PubMed:16807401]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport in mature neurons. Transport occurs under isotonic conditions, but is activated 20-fold by cell swelling. Important for Cl(-) homeostasis in n...
Gene Name
SLC12A5
Uniprot ID
Q9H2X9
Uniprot Name
Solute carrier family 12 member 5
Molecular Weight
126182.49 Da
References
  1. Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 (KCC2) in the Purkinje cells of embryonic mouse cerebellum. Neurosci Res. 2007 Feb;57(2):322-5. Epub 2006 Nov 28. [PubMed:17134779]
  2. Tornberg J, Segerstrale M, Kulesskaya N, Voikar V, Taira T, Airaksinen MS: KCC2-deficient mice show reduced sensitivity to diazepam, but normal alcohol-induced motor impairment, gaboxadol-induced sedation, and neurosteroid-induced hypnosis. Neuropsychopharmacology. 2007 Apr;32(4):911-8. Epub 2006 Aug 16. [PubMed:16936706]
  3. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
  4. Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 in granule cells of the early postnatal mouse cerebellum with special reference to the synapse formation. Neuroscience. 2006 Dec;143(3):757-67. Epub 2006 Sep 27. [PubMed:17008020]
  5. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Rubidium ion transmembrane transporter activity
Specific Function
Mediates electroneutral potassium-chloride cotransport. May be activated by cell swelling. May contribute to cell volume homeostasis in single cells.
Gene Name
SLC12A6
Uniprot ID
Q9UHW9
Uniprot Name
Solute carrier family 12 member 6
Molecular Weight
127615.745 Da
References
  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [PubMed:16943364]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May mediate K(+) uptake into Deiters' cells in the cochlea and contribute to K(+) recycling in the inner ear....
Gene Name
SLC12A7
Uniprot ID
Q9Y666
Uniprot Name
Solute carrier family 12 member 7
Molecular Weight
119104.84 Da
References
  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [PubMed:16943364]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May contribute to cell volume homeostasis in single cells. May be involved in the regulation of basolateral C...
Gene Name
SLC12A4
Uniprot ID
Q9UP95
Uniprot Name
Solute carrier family 12 member 4
Molecular Weight
120648.73 Da
References
  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [PubMed:16943364]

Drug created on June 13, 2005 07:24 / Updated on November 30, 2020 13:38

Cs molecular health 1